Stroke Management Market By Type (Diagnostics, Therapeutics, Software), By Application (Ischemic Stroke, Haemorrhagic Stroke): Global Opportunity Analysis and Industry Forecast, 2022-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Stroke Management Market," The stroke management market was valued at $36.1 billion in 2022, and is estimated to reach $74 billion by 2032, growing at a CAGR of 7.4% from 2022 to 2032.

A stroke is a medical condition that occurs when the blood supply to the brain is abruptly cut off due to rupturing of blood vessels or blockage in blood supply to brain. This leads to depletion of oxygen to brain tissues, which results in the rapid death of brain cells. There are mainly three types of strokes namely ischemic stroke, transient ischemic attack, and hemorrhagic stroke. A comprehensive approach to the diagnosis and treatment of people who suffered from stroke is called stroke management. The diagnosis of stroke includes magnetic resonance imaging, carotid ultrasound, cerebral angiography, blood tests, and others. Stoke can be treated with tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive medicines.

The stroke management market growth is driven by rising incidence of stroke, technological development in diagnostic imaging, and surge in adoption of telemedicine for stroke management. Factors such as

1) sedentary lifestyle, unhealthy diets, and high stress levels leads to rise in incidences of stroke. For instance, according to the data published by World Health Organization (WHO), on World Stroke Day 2022, reported that stroke is the second leading cause of death across the globe. As per the same source, the lifetime risk of developing a stroke has increased by 50% and currently 1 in 4 people is estimated to have a stroke in their lifetime. This rise in stroke incidences has led to a higher demand for effective treatments and management strategies, which in turn drives the growth of the stroke management market.

In addition, the technological advancement in the diagnostic techniques also drives the market growth. The advanced imaging technologies such as

1) magnetic resonance imaging and angiography systems have improved the diagnosis of stroke and enhanced patient care. For instance, Siemens Healthineers, a global medical technology company has received the Food and Drug Administration (FDA) approval for its ARTIS icono ceiling. ARTIS icono ceiling is an angiography system used for the advanced procedures in the interventional cardiology. Thus, technological advancement in the stroke imaging techniques further boost the market growth.

However, the high cost of stroke diagnosis and treatment limit the growth of stroke management market. The economic burden of stroke is the major factor hampering the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the growth of stroke management market.

On the other hand, surge in adoption of artificial intelligence for stroke management, increase in awareness about preventive healthcare, and rise in geriatric population in developing countries are expected to create lucrative opportunities for market growth during the forecast period.

The stroke management market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into diagnostics, therapeutics, and software. The diagnostic segment is further categorized into magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The therapeutics segment is further divided into tissue plasminogen activator, anticoagulant, antiplatelet, and antihypertensive. As per application, the market is bifurcated into ischemic stroke and hemorrhagic stroke.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global stroke management market are Abbott Laboratories, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardinal Health, General Electric Company, Medtronic, Siemens AG, Aidoc, Brainomix, VasSol Inc., Qure.ai, Viz.ai, Inc., METHINKS, B Braun SE, iSchemaView, Inc., NeuraSignal, Inc., Deepnoid Co., Ltd., Heuron Co., Ltd., JLK, Koninklijke Philips N.V., and Merck & Co. Inc. Key players operating in the market have adopted product approval, acquisition, partnership, and product launch as their key strategies to expand their market share and product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the stroke management market analysis from 2022 to 2032 to identify the prevailing stroke management market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the stroke management market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global stroke management market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Criss-cross segment analysis- market size and forecast
Expanded list for Company Profiles
Key player details (including location, contact details, supplier/vendor network etc. in excel format)
SWOT Analysis

Key Market Segments

By Type

Diagnostics
- Type
- Magnetic Resonance Imaging
- Carotid Ultrasound
- Cerebral Angiography
- Electrocardiography
- Echocardiography
- Others
Therapeutics
- Type
- Tissue Plasminogen Activator
- Anticoagulant
- Antiplatelet
- Antihypertensive
Software

By Application

Ischemic Stroke
Haemorrhagic Stroke

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Boston Scientific Corporation
Bristol-Myers Squibb Company
General Electric Company
Medtronic
Aidoc
Brainomix
Qure.ai
METHINKS
iSchemaView, Inc.
Deepnoid Co., Ltd.
Heuron Co., Ltd.
B. Braun SE
Koninklijke Philips N.V.
Abbott Laboratories
Cardinal Health
Siemens AG
VasSol Inc.
Viz.ai, Inc.
NeuraSignal, Inc.
JLK
Merck & Co. Inc

Product Code: A00539

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. Moderate intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in the incidences of stroke
  - 3.4.1.2. Technological development in stroke management
  - 3.4.1.3. Significant increase in stroke awareness
- 3.4.2. Restraints
  - 3.4.2.1. High cost of stroke diagnostics and treatment
- 3.4.3. Opportunities
  - 3.4.3.1. Artificial intelligence and machine learning are revolutionizing stroke management

CHAPTER 4: STROKE MANAGEMENT MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Diagnostics
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Diagnostics Stroke Management Market by Type
4.3. Therapeutics
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.3.4. Therapeutics Stroke Management Market by Type
4.4. Software
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: STROKE MANAGEMENT MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Ischemic Stroke
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Haemorrhagic Stroke
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country

CHAPTER 6: STROKE MANAGEMENT MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by Type
- 6.2.3. Market size and forecast, by Application
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Market size and forecast, by Type
  - 6.2.4.1.2. Market size and forecast, by Application
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Market size and forecast, by Type
  - 6.2.4.2.2. Market size and forecast, by Application
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Market size and forecast, by Type
  - 6.2.4.3.2. Market size and forecast, by Application
6.3. Europe
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by Type
- 6.3.3. Market size and forecast, by Application
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Market size and forecast, by Type
  - 6.3.4.1.2. Market size and forecast, by Application
  - 6.3.4.2. France
  - 6.3.4.2.1. Market size and forecast, by Type
  - 6.3.4.2.2. Market size and forecast, by Application
  - 6.3.4.3. UK
  - 6.3.4.3.1. Market size and forecast, by Type
  - 6.3.4.3.2. Market size and forecast, by Application
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Market size and forecast, by Type
  - 6.3.4.4.2. Market size and forecast, by Application
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Market size and forecast, by Type
  - 6.3.4.5.2. Market size and forecast, by Application
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Market size and forecast, by Type
  - 6.3.4.6.2. Market size and forecast, by Application
6.4. Asia-Pacific
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by Type
- 6.4.3. Market size and forecast, by Application
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. China
  - 6.4.4.1.1. Market size and forecast, by Type
  - 6.4.4.1.2. Market size and forecast, by Application
  - 6.4.4.2. Japan
  - 6.4.4.2.1. Market size and forecast, by Type
  - 6.4.4.2.2. Market size and forecast, by Application
  - 6.4.4.3. India
  - 6.4.4.3.1. Market size and forecast, by Type
  - 6.4.4.3.2. Market size and forecast, by Application
  - 6.4.4.4. Australia
  - 6.4.4.4.1. Market size and forecast, by Type
  - 6.4.4.4.2. Market size and forecast, by Application
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Market size and forecast, by Type
  - 6.4.4.5.2. Market size and forecast, by Application
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Market size and forecast, by Type
  - 6.4.4.6.2. Market size and forecast, by Application
6.5. LAMEA
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by Type
- 6.5.3. Market size and forecast, by Application
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Market size and forecast, by Type
  - 6.5.4.1.2. Market size and forecast, by Application
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Market size and forecast, by Type
  - 6.5.4.2.2. Market size and forecast, by Application
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Market size and forecast, by Type
  - 6.5.4.3.2. Market size and forecast, by Application
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Market size and forecast, by Type
  - 6.5.4.4.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. Abbott Laboratories
- 8.1.1. Company overview
- 8.1.2. Key executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
8.2. B. Braun SE
- 8.2.1. Company overview
- 8.2.2. Key executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
8.3. Boston Scientific Corporation
- 8.3.1. Company overview
- 8.3.2. Key executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
8.4. Bristol-Myers Squibb Company
- 8.4.1. Company overview
- 8.4.2. Key executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
8.5. Cardinal Health
- 8.5.1. Company overview
- 8.5.2. Key executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
- 8.5.6. Business performance
8.6. General Electric Company
- 8.6.1. Company overview
- 8.6.2. Key executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
- 8.6.7. Key strategic moves and developments
8.7. Medtronic
- 8.7.1. Company overview
- 8.7.2. Key executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
- 8.7.6. Business performance
8.8. Siemens AG
- 8.8.1. Company overview
- 8.8.2. Key executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
8.9. JLK
- 8.9.1. Company overview
- 8.9.2. Key executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
8.10. Heuron Co., Ltd.
- 8.10.1. Company overview
- 8.10.2. Key executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Key strategic moves and developments
8.11. Deepnoid Co., Ltd.
- 8.11.1. Company overview
- 8.11.2. Key executives
- 8.11.3. Company snapshot
- 8.11.4. Operating business segments
- 8.11.5. Product portfolio
8.12. NeuraSignal, Inc.
- 8.12.1. Company overview
- 8.12.2. Key executives
- 8.12.3. Company snapshot
- 8.12.4. Operating business segments
- 8.12.5. Product portfolio
- 8.12.6. Key strategic moves and developments
8.13. Aidoc
- 8.13.1. Company overview
- 8.13.2. Key executives
- 8.13.3. Company snapshot
- 8.13.4. Operating business segments
- 8.13.5. Product portfolio
8.14. Brainomix
- 8.14.1. Company overview
- 8.14.2. Key executives
- 8.14.3. Company snapshot
- 8.14.4. Operating business segments
- 8.14.5. Product portfolio
- 8.14.6. Key strategic moves and developments
8.15. METHINKS
- 8.15.1. Company overview
- 8.15.2. Key executives
- 8.15.3. Company snapshot
- 8.15.4. Operating business segments
- 8.15.5. Product portfolio
- 8.15.6. Key strategic moves and developments
8.16. Viz.ai, Inc.
- 8.16.1. Company overview
- 8.16.2. Key executives
- 8.16.3. Company snapshot
- 8.16.4. Operating business segments
- 8.16.5. Product portfolio
- 8.16.6. Key strategic moves and developments
8.17. iSchemaView, Inc.
- 8.17.1. Company overview
- 8.17.2. Key executives
- 8.17.3. Company snapshot
- 8.17.4. Operating business segments
- 8.17.5. Product portfolio
- 8.17.6. Key strategic moves and developments
8.18. Qure.ai
- 8.18.1. Company overview
- 8.18.2. Key executives
- 8.18.3. Company snapshot
- 8.18.4. Operating business segments
- 8.18.5. Product portfolio
- 8.18.6. Key strategic moves and developments
8.19. VasSol Inc.
- 8.19.1. Company overview
- 8.19.2. Key executives
- 8.19.3. Company snapshot
- 8.19.4. Operating business segments
- 8.19.5. Product portfolio
8.20. Koninklijke Philips N.V.
- 8.20.1. Company overview
- 8.20.2. Key executives
- 8.20.3. Company snapshot
- 8.20.4. Operating business segments
- 8.20.5. Product portfolio
- 8.20.6. Business performance
8.21. Merck & Co. Inc
- 8.21.1. Company overview
- 8.21.2. Key executives
- 8.21.3. Company snapshot
- 8.21.4. Operating business segments
- 8.21.5. Product portfolio
- 8.21.6. Business performance
- 8.21.7. Key strategic moves and developments